文献速递冠心病心力衰竭与心肌病

两项心肌梗死试验的个体参与者数据分析:醛固酮阻断的获益

Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction.
PubMed 文献 · Heart · 2018-04-25

该预设汇总分析纳入两项多中心优效性试验中STEMI患者的个体数据,随机接受MRA方案或对照。中位随访188天,MRA组全因死亡及全因死亡或复苏后猝死复合终点均显著低于对照组,提示MRA方案与STEMI患者死亡减少相关。

要点

  • STEMI患者使用MRA方案与全因死亡风险降低相关。
  • 全因死亡或复苏后猝死复合终点在MRA组也显著降低。
  • 心血管死亡和室颤发生率在MRA组呈下降趋势但未达统计学显著。

核心结论

  • 与标准治疗相比,MRA方案与STEMI患者死亡及死亡或复苏后猝死减少相关。

研究设计与样本

  • 预设汇总分析纳入两项多中心优效性试验中症状发作72小时内随机化的STEMI患者个体数据。

主要发现

  • MRA组1118例、对照组1123例,中位随访188天。
  • MRA组全因死亡5例(0.4%),对照组17例(1.5%),adjHR 0.31(95%CI 0.11-0.86,p=0.03)。
  • MRA组全因死亡或复苏后猝死6例(0.5%),对照组22例(2%),adjHR 0.26(95%CI 0.10-0.65,p=0.004)。
  • 心血管死亡(p=0.06)和室颤(p=0.08)在MRA组呈下降趋势。

关键数值与推荐

  • MRA方案包括静脉坎利酸钾200 mg后口服螺内酯25 mg每日一次,或口服依普利酮25-50 mg。

临床怎么用

  • 对于STEMI患者,可考虑在标准治疗基础上使用MRA方案以降低死亡风险。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Two recent randomised trials studied the benefit of mineralocorticoid receptor antagonists (MRAs) in ST-segment elevation myocardial infarction (STEMI) irrespective or in absence of heart failure. The studies were both undersized to assess hard clinical endpoints. A pooled analysis was preplanned by the steering committees. METHODS: We conducted a prespecified meta-analysis of patient-level data of patients with STEMI recruited in two multicentre superiority trials, randomised within 72 hours after symptom onset. Patients were allocated (1:1) to two MRA regimens: (1) an intravenous bolus of potassium canrenoate (200 mg) followed by oral spironolactone (25 mg once daily) versus standard therapy or (2) oral eplerenone (25-50 mg) versus placebo. The primary and key secondary outcomes, all-cause death and the composite of all-cause death or resuscitated sudden death, respectively, were assessed in the intention-to-treat population using a Cox model stratified on the study identifier. RESULTS: Patients were randomly assigned to receive (n=1118) or not the MRA regimen (n=1123). After a median follow-up time of 188 days, the primary and secondary outcomes occurred in 5 (0.4%) and 17 (1.5%) patients (adjusted HR (adjHR) 0.31, 95% CI 0.11 to 0.86, p=0.03) and 6 (0.5%) and 22 (2%) patients (adjHR 0.26, 95% CI 0.10 to 0.65, p=0.004) in the MRA and control groups, respectively. There were also trends towards lower rates of cardiovascular death (p=0.06) and ventricular fibrillation (p=0.08) in the MRA group. CONCLUSION: Our analysis suggests that compared with standard therapy, MRA regimens are associated with a reduction of death and death or resuscitated sudden death in STEMI.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Beygui F, Van Belle E, Ecollan P, et al. Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction. Heart. 2018. PMID: 29695512. doi:10.1136/heartjnl-2018-312950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。